Vnitr Lek 2012, 58(5):354-356

Interactions between glucocorticoids and warfarin in chronic inflammatory (autoimmune) diseases

L. Hromádková*, J. Vlček
Katedra sociální a klinické farmacie Farmaceutické fakulty UK Hradec Králové, vedoucí prof. RNDr. Jiří Vlček, CSc.

Glucocorticosteroids are still very important part of the treatment of chronic inflammatory disorders. Their use is often accompanied by unpleasant adverse effects, problems associated with withdrawal during their long-term use and interactions with concomitantly administered drugs. One of the important interactions that may often occur in clinical practice is interaction with warfarin. Despite the fact that as glucocorticosteroids so warfarin are used for many years and seem to be completely known, their co-administration is still accompanied by uncertainties. The interaction may have pharmacodynamic or pharmacokinetic character and both types result in increased risk of bleeding. The pharmacodynamic interaction can be expected to increase a risk of gastrointestinal bleeding to which a gastrotoxicity of glucocorticosteroids contributes. A pharmacokinetic interaction is considered to influence a hepatic metabolism of warfarin and to increase its availability. The exact mechanism is still not fully understood. Manifestations of both types of interactions are taken up with a delay. Co-administration requires increased attention and close monitoring of international normalized ratio. At higher doses of glucocorticosteroids proton pump inhibitors are also effective in prevention of gastrotoxicity.

Keywords: glucocorticosteroids; warfarin; interaction; rheumatology; autoimmune disorders

Received: October 11, 2011; Accepted: December 6, 2011; Published: May 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hromádková L, Vlček J. Interactions between glucocorticoids and warfarin in chronic inflammatory (autoimmune) diseases. Vnitr Lek. 2012;58(5):354-356.
Download citation

References

  1. Product information. Medrol (methylprednisolone). Pfizer Inc., Prague, Czech Republic, November 2009.
  2. Carson JL, Strom BL, Schinnar R et al. The low risk of upper gastrointestinal bleeding in pa-tients dispensed corticosteroids. Am J Med 1991; 91: 223-228. Go to original source... Go to PubMed...
  3. Hazlewood KA, Fugate SE, Harrison DL. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006; 40: 2101-2106. Go to original source... Go to PubMed...
  4. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler 1997; 3: 248-249. Go to original source... Go to PubMed...
  5. Costedoat-Chalumeau N, Amoura Z, Aymard G et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 2000; 132: 631-635. Go to original source... Go to PubMed...
  6. Bai XB, Liu CX. Overview of major CYP450 isoforms and "Cocktail Approach". Asian J Drug Metabolism Pharmacokinetics 2005; 5: 257-264.
  7. Sharif Z. Pharmacokinetics, metabolism, and drug interactions of atypical antipsychotics in special population. J Clin Psychiatry 2003; 5 (Suppl 6): 22-25.
  8. DRUGDEX® System [intranet database]. Version 5.1. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.